849 related articles for article (PubMed ID: 33655969)
1. Tacrolimus-induced epilepsy with primary membranous nephropathy: A case report.
Yang Y; Zhang L; Mo Y; Ren R; Wang F
Medicine (Baltimore); 2021 Mar; 100(9):e24989. PubMed ID: 33655969
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial.
Praga M; Barrio V; Juárez GF; Luño J;
Kidney Int; 2007 May; 71(9):924-30. PubMed ID: 17377504
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus in resistant primary membranous nephropathy--a report of 3 cases.
Szeto CC; Leung CB; Lai FM; Li PK
Clin Nephrol; 2003 Apr; 59(4):293-6. PubMed ID: 12708570
[TBL] [Abstract][Full Text] [Related]
4. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.
Ramachandran R; Hn HK; Kumar V; Nada R; Yadav AK; Goyal A; Kumar V; Rathi M; Jha V; Gupta KL; Sakhuja V; Kohli HS
Nephrology (Carlton); 2016 Feb; 21(2):139-46. PubMed ID: 26205759
[TBL] [Abstract][Full Text] [Related]
5. Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus.
Caro J; Gutiérrez-Solís E; Rojas-Rivera J; Agraz I; Ramos N; Rabasco C; Espinosa M; Valera A; Martín M; Frutos MÁ; Perea L; Juárez GF; Ocaña J; Arroyo D; Goicoechea M; Fernández L; Oliet A; Hernández Y; Romera A; Segarra A; Praga M;
Nephrol Dial Transplant; 2015 Mar; 30(3):467-74. PubMed ID: 25274748
[TBL] [Abstract][Full Text] [Related]
6. Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy.
Peng L; Wei SY; Li LT; He YX; Li B
J Formos Med Assoc; 2016 Jan; 115(1):11-8. PubMed ID: 26315481
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tacrolimus-based treatment for nephrotic idiopathic membranous nephropathy in young adults: A retrospective study.
Zhang XJ; Ji CF; Yuan JZ; Wang L; Zhang J; Fang W; Bai DF; Hu Z
Kaohsiung J Med Sci; 2019 Oct; 35(10):633-639. PubMed ID: 31225949
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Tacrolimus Versus Cyclophosphamide for Primary Membranous Nephropathy: A Meta-Analysis.
Zhu LB; Liu LL; Yao L; Wang LN
Drugs; 2017 Feb; 77(2):187-199. PubMed ID: 28084563
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy.
Liang Q; Li H; Xie X; Qu F; Li X; Chen J
Ren Fail; 2017 Nov; 39(1):512-518. PubMed ID: 28562168
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis.
Ren S; Wang Y; Xian L; Toyama T; Jardine M; Li G; Perkovic V; Hong D
PLoS One; 2017; 12(9):e0184398. PubMed ID: 28898290
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy and safety of tacrolimus monotherapy and cyclophosphamide combined with glucocorticoid in the treatment of adult primary membranous nephropathy: protocol of a multicenter, randomized, controlled, open study.
Chen S; Ren S; Wang AY; Tran H; Li Z; Cheng X; Liu M; Li G; Wang L; Hong D
Trials; 2020 Feb; 21(1):219. PubMed ID: 32093742
[TBL] [Abstract][Full Text] [Related]
12. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.
Fernández-Juárez G; Rojas-Rivera J; Logt AV; Justino J; Sevillano A; Caravaca-Fontán F; Ávila A; Rabasco C; Cabello V; Varela A; Díez M; Martín-Reyes G; Diezhandino MG; Quintana LF; Agraz I; Gómez-Martino JR; Cao M; Rodríguez-Moreno A; Rivas B; Galeano C; Bonet J; Romera A; Shabaka A; Plaisier E; Espinosa M; Egido J; Segarra A; Lambeau G; Ronco P; Wetzels J; Praga M;
Kidney Int; 2021 Apr; 99(4):986-998. PubMed ID: 33166580
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and safety of different tacrolimus concentrations for the treatment of patients with idiopathic membranous nephropathy.
Wang Q; Li M; Cheng X; Xu G
Sci Rep; 2021 Jun; 11(1):13274. PubMed ID: 34168218
[TBL] [Abstract][Full Text] [Related]
14. Electron-Dense Deposition Patterns and the Outcomes of Nephrotic Idiopathic Membranous Nephropathy Treated with Tacrolimus in Chinese Adults.
Xiang X; Feng Z; Jiang Q; Huang D; Meng Z; Luo Z
Med Sci Monit; 2021 Apr; 27():e930500. PubMed ID: 33896931
[TBL] [Abstract][Full Text] [Related]
15. Good response of membranous lupus nephritis to tacrolimus.
Maruyama M; Yamasaki Y; Sada K; Sarai A; Ujike K; Maeshima Y; Nakamura Y; Sugiyama H; Makino H
Clin Nephrol; 2006 Apr; 65(4):276-9. PubMed ID: 16629227
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis.
Lin W; Li HY; Lin S; Zhou T
Drug Des Devel Ther; 2019; 13():2179-2186. PubMed ID: 31308629
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.
Chen Y; Schieppati A; Chen X; Cai G; Zamora J; Giuliano GA; Braun N; Perna A
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD004293. PubMed ID: 25318831
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus in membranous nephropathy.
Wetzels JF
Kidney Int; 2008 Jan; 73(2):238. PubMed ID: 18165814
[No Abstract] [Full Text] [Related]
19. Membranous nephropathy caused by rheumatoid arthritis.
Iida A; Wada Y; Hayashi J; Tachibana S; Inaba T; Iyoda M; Honda K; Shibata T
CEN Case Rep; 2019 Nov; 8(4):233-238. PubMed ID: 31037495
[TBL] [Abstract][Full Text] [Related]
20. De novo postallogeneic hematopoietic stem cell transplant membranous nephropathy.
Numata A; Morishita Y; Mori M; Saito O; Takemoto F; Ando Y; Muto S; Yumura W; Kusano E
Exp Clin Transplant; 2013 Feb; 11(1):75-8. PubMed ID: 22809119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
